Literature DB >> 30782299

Schizandrol A reverses multidrug resistance in resistant chronic myeloid leukemia cells K562/A02.

Nurguli Arken.   

Abstract

Overexpression of P-gp is the main cause of multidrug resistance (MDR) and chemotherapeutic failure in leukemia. In this study, the multidrug resistance reverse effect of Schizandrol A (SchA) was demonstrated with P-gp overexpressed drug-resistant K562/A02 cells. SchA had almost no cytotoxic activity, the EC50 value reversed to DOX was in the nanomole range of (707 ± 29nM) and had a high selectivity index (> 113) to normal cells. DOX accumulation and Rh123 efflux tests demonstrated that the MDR reversal activity of SchA was induced by inhibiting P-gp function. Western blotting assay showed that SchA down-regulated the expression of P-gp by inhibiting the PI3K / Akt signaling pathway, which was also a key factor in reversal activity. Therefore, SchA may be a potential candidate for natural MDR reversal agents.

Entities:  

Keywords:  Chronic myeloid leukemia; Multidrug resistance; P-gp; Reversal activity.; Schizandrol A

Mesh:

Substances:

Year:  2019        PMID: 30782299

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  2 in total

1.  Protective autophagy or autophagic death: effects of BEZ235 on chronic myelogenous leukemia.

Authors:  Pengliang Xin; Wenqian Xu; Xiongpeng Zhu; Chuntuan Li; Yan Zheng; Tingjin Zheng; Wenzhao Cheng; Qunyi Peng
Journal:  Cancer Manag Res       Date:  2019-08-22       Impact factor: 3.989

2.  Molecular Mechanism of the Regulatory Effect of Schisandrol A on the Immune Function of Mice Based on a Transcription Factor Regulatory Network.

Authors:  Guangyu Xu; Yanbo Feng; Han Li; Cong Chen; He Li; Chunmei Wang; Jianguang Chen; Jinghui Sun
Journal:  Front Pharmacol       Date:  2021-12-20       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.